The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab

OBJECTIVES: To assess whether treatment with one of three novel biological DMARDs; rituximab, abatacept or tocilizumab reduce cardiovascular disease (CVD) risk factors in patients with rheumatoid arthritis (RA). METHODS: This is an open, observational and prospective study with visits at baseline, 3...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS One
Autori principali: Provan, Sella Aarrestad, Berg, Inger Jorid, Hammer, Hilde Berner, Mathiessen, Alexander, Kvien, Tore Kristian, Semb, Anne Grete
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2015
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482693/
https://ncbi.nlm.nih.gov/pubmed/26114946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0130709
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi